COVID-19 IN PATIENTS WITH PRE-EXISTING NEUROLOGIC DISORDERS
Svetlana Blitshteyn, MD
Clinical Assistant Professor of Neurology
University at Buffalo Jacobs School of Medicine and Biomedical Sciences
E-mail [email protected]
Thank you for electing to participate in a research study on COVID-19 in patients with pre-existing neurologic disorders. The purpose of the study is to collect data on COVID-19 and its possible impact on neurologic disorders in patients with pre-existing neurologic disorders whose COVID-19 was confirmed by testing. This study is open to neurologists with MD/DO degree practicing in the United States. Your participation is voluntary and is completely anonymous. You can choose to identify yourself by name in the survey if you wish your name to be included in the future publication, but disclosing your name is your choice and not a requirement for the completion of the survey.
The survey will take about 5 min to complete. You will be asked to enter the patient’s data anonymously without personable identification information. You will be asked to provide the state where you practice neurology, but you will not be required to provide any personable identification information to complete the survey. There are no risks to you or your patients: information that you provide will help neurologists and other physicians learn how COVID-19 may impact patients with pre-existing neurologic disorders and how to improve care of these patients.
Please complete the survey for each patient with pre-existing neurologic disorder and COVID-19, confirmed by testing, that you personally evaluated, whether as a one-time consult or multiple follow-up appointments. Inpatient, outpatient and teleneurology consults and follow-up appointments are acceptable for this study. If you have more than one patient with test-confirmed COVID-19, please complete the survey for each patient that you evaluated.
The study has been approved by the IRB at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences. If you have any questions or concerns about the study, please contact the principle investigator by e-mail [email protected] or phone 716-531-4598.